Surgical Management of Interdental Papilla Recession With Advanced Platelet Rich Fibrin or Connective Tissue Graft

NCT ID: NCT05031169

Last Updated: 2021-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

deficient interdental papillae witt be surgically reconstructed. in one group, connective tissue graft (SCTG) will be used for papillae augmentation, while in the other group, advanced platelet rich fibrin (A-PRF). the height of the papillae will be measured preoperatively as well as post operatively at 3, 6 ,9 and 12 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to compare the effect of A-PRF membrane to SCTG when used as grafting material with the Han and Takei's approach to reconstruct receding interdental papilla and assess deference in papilla height between the study groups.

The clinical parameters that will be evaluated are:

* Papilla height (PH)
* Clinical attachment level (CAL)
* Probing depth (PD)
* Post-operative patients' satisfaction about the esthetic outcome
* Post-operative pain level among patients

Study settings:

This study will be conducted in the postgraduate periodontology clinics in the faculty of dentistry, Cairo University. The participants will be selected from the outpatient clinic of the department.

interventionsa:

The first visit:

* Eligible participants will be interviewed to report medical and dental histories.
* The participants will receive full mouth dental and periodontal examination.
* Initial periodontal treatment (supragingival scaling and sub gingival debridement) as indicated.
* Patients will be given oral hygiene instruction on proper tooth brushing and flossing.
* They will be advised to use chlorhexidine mouth wash 0.12% twice daily for 2 weeks.

Second visit:

After 4-6 weeks of initial therapy, patients will be re-examined, and the baseline clinical parameters will be recorded as follows:

* Full mouth plaque index and gingival index.
* Site specific plaque index and gingival index.
* Type of Papilla deficiency (classification).
* Papilla height
* Clinical attachment level
* Probing depth

The patients then will be randomly allocated to one of the study groups.

Test group:

Deficient papillae in this group will be treated surgically and A-PRF membrane will be used as a grafting material.

Preparation of A-PRF:

A-PRF preparation protocol will be as described by (Clark et al. 2018):

A blood sample of 10 ml will be obtained from the patient and immediately centrifuged at 1300 rpm for 8 minutes.

Control group:

In this group, papilla recession will be treated surgically and the SCTG will be used as a grafting material.

sample size calculation was based on a previous study. fourteen experimental subjects and 14 control subjects are required to be able to reject the null hypothesis that the population means of the experimental and the control groups are equal with probability (power) 0.8. The type I error probability associated with this test of this null hypothesis is 0.05.

To compensate for anticipated missing data during follow up, this number is increased to 16 per group.

Recruitment

* Patients will be selected from the outpatient clinic of the Oral Medicine and Periodontology Department, Faculty of Oral and Dental Medicine-Cairo University
* Screening of patients will continue until the target sample is achieved.

Allocation

Randomization:

Patients will be randomly assigned to either test or control group using computer generated randomization (www.randomizer.org) which will be performed by the supervisor. The patients will be allocated to either test or control group.

Allocation concealment mechanism:

The two groups will be equally prepared for both surgical procedures. Then the decision of which group will receive papilla treatment with A-PRF (test) and which will receive papilla treatment with SCTG (control) will be taken according to the randomized numbers placed in opaque sealed envelopes. The number will be picked by the supervisor.

Implementation:

• All patients who provide an informed consent for participation as well as fulfill the inclusion criteria will be randomized.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recession

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized clinical trial with 1:1 ratio.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A-PRF

Surgical treatment A-PRF membrane

Group Type EXPERIMENTAL

interdental papilla surgical reconstructiion

Intervention Type PROCEDURE

Surgical treatment of receding interdentalpapillae

SCTG

Surgical treatment with SCTG

Group Type ACTIVE_COMPARATOR

interdental papilla surgical reconstructiion

Intervention Type PROCEDURE

Surgical treatment of receding interdentalpapillae

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

interdental papilla surgical reconstructiion

Surgical treatment of receding interdentalpapillae

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be healthy adults older than 18 years of age and presenting at least one deficient papilla with papilla presence index 2 or 3
* Have Interproximal CAL ≤ 3 mm
* Have probing depth ≤ 3mm
* Distance between the alveolar bone crest and contact point is less than 7mm.

Exclusion Criteria

* Smoking.
* Pregnancy and lactation.
* Carious and non-carious cervical lesion in the involved teeth around the papilla.
* Restoration in teeth around the papilla (filling, crown, bridge, facings, clasp of a partial denture).
* Open contacts and non-vital teeth
* Poor oral hygiene with plaque index \> 20 %.
* Tooth mobility
* History of medication in the previous 3 months
* History of periodontal surgery in the site to be treated in the past 12 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sanabel Osama Omran Barakat

Ph d candidate

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hani ElNahass, Ph D

Role: STUDY_CHAIR

Cairo University

Samar ElKohouly, Ph D

Role: PRINCIPAL_INVESTIGATOR

Cairo University

sanabel barakat, MSC

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Dentistry

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

sanabel barakat

Role: CONTACT

00201550071457

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hani ElNahass, PhD

Role: primary

01000252603

References

Explore related publications, articles, or registry entries linked to this study.

Ahila E, Saravana Kumar R, Reddy VK, Pratebha B, Jananni M, Priyadharshini V. Augmentation of Interdental Papilla with Platelet-rich Fibrin. Contemp Clin Dent. 2018 Apr-Jun;9(2):213-217. doi: 10.4103/ccd.ccd_812_17.

Reference Type BACKGROUND
PMID: 29875563 (View on PubMed)

Cardaropoli D, Re S, Corrente G, Abundo R. Reconstruction of the maxillary midline papilla following a combined orthodontic-periodontic treatment in adult periodontal patients. J Clin Periodontol. 2004 Feb;31(2):79-84. doi: 10.1111/j.0303-6979.2004.00451.x.

Reference Type BACKGROUND
PMID: 15016030 (View on PubMed)

Augusta, Maria and Matas Hennig. 2016. "Absence of Interdental Papilla - Systematic Review of Available Therapeutic Modalities." Stomatos 22(43):31-43.

Reference Type BACKGROUND

Chaulkar PP, Mali RS, Mali AM, Lele PA, Patil PA. A comparative evaluation of papillary reconstruction by modified Beagle's technique with the Beagle's surgical technique: A clinical and radiographic study. J Indian Soc Periodontol. 2017 May-Jun;21(3):218-223. doi: 10.4103/jisp.jisp_166_17.

Reference Type BACKGROUND
PMID: 29440789 (View on PubMed)

Clark D, Rajendran Y, Paydar S, Ho S, Cox D, Ryder M, Dollard J, Kao RT. Advanced platelet-rich fibrin and freeze-dried bone allograft for ridge preservation: A randomized controlled clinical trial. J Periodontol. 2018 Apr;89(4):379-387. doi: 10.1002/JPER.17-0466.

Reference Type BACKGROUND
PMID: 29683498 (View on PubMed)

Eren G, Atilla G. Platelet-rich fibrin in the treatment of localized gingival recessions: a split-mouth randomized clinical trial. Clin Oral Investig. 2014 Nov;18(8):1941-8. doi: 10.1007/s00784-013-1170-5. Epub 2013 Dec 22.

Reference Type BACKGROUND
PMID: 24362634 (View on PubMed)

Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, Landes C, Sader R, Kirkpatrick C, Choukroun J. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014 Dec;40(6):679-89. doi: 10.1563/aaid-joi-D-14-00138.

Reference Type BACKGROUND
PMID: 24945603 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PER 331

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Interdental Guided Creeping Technique
NCT06264869 NOT_YET_RECRUITING NA
Effect of I-PRF After Gingivectomy
NCT07174934 NOT_YET_RECRUITING NA